Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 25 versus GRAFAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 25 versus GRAFAPEX.
CAPOZIDE 50/25 vs GRAFAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
GRAFAPEX is a monoclonal antibody that binds to and inhibits the activity of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
One tablet (captopril 50 mg / hydrochlorothiazide 25 mg) orally once daily; may increase to two tablets daily if needed.
10-20 mg orally once daily, maximum 40 mg per day.
None Documented
None Documented
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: dosing interval typically 12-24 hours.
Terminal elimination half-life: 12 hours (range 10-14 hours); clinical context: dosing interval recommended every 24 hours to maintain therapeutic levels
Captopril: 95% renal (primarily unchanged). Hydrochlorothiazide: 95% renal (unchanged).
Renal: 60% as unchanged drug; biliary/fecal: 30%; minor metabolism: 10%
Category C
Category C
ACE Inhibitor/Diuretic Combination
ACE Inhibitor